Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Plasma suPAR is lowered by smoking cessation - a randomised controlled study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A totally new system is needed for drug research and development

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Patients not patents: Drug research and development as a public enterprise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediction of coronary heart disease or heart failure using high-sensitivity cardiac troponin T: a pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Familial hypercholesterolaemia: cholesterol efflux and coronary disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) is a stable inflammatory biomarker. In patients, suPAR is a marker of disease presence, severity and prognosis. In the general population, suPAR is predictive of disease development, such as diabetes and cardiovascular disease and, in smokers, predictive of long-term lung cancer development. Whether smoking cessation impacts the suPAR level is unknown.

MATERIALS AND METHODS: Forty-eight smokers were randomized into three groups of 16: 1) continued to smoke 20 cigarettes per day, 2) refrained from smoking and used transdermal nicotine patches and 3) refrained from smoking and used placebo patches. Non-smokers were included for comparison. suPAR and C-reactive protein (CRP) levels were measured by ELISA.

RESULTS: At baseline, the suPAR level was significantly higher in the 48 smokers (median 3.2 ng/ml, IQR (2.5-3.9)) than in 46 never smokers (1.9 ng/ml (1.7-2.2)). In smokers randomised to smoking cessation, suPAR levels after four weeks of stopping were decreased and no longer significantly different from the never smokers values. SuPAR decreased in both those who received a placebo as well as nicotine patch. Interestingly, those with the highest suPAR level at time of smoking were also those with the highest level of suPAR after smoking cessation. In contrast, smoking or smoking cessation had no influence on CRP levels.

CONCLUSION: Our study suggest that the suPAR level may aid to personalize the risk of smoking by identifying those smokers with the highest risk of developing disease and who may have the most benefit of smoking cessation. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Clinical Investigation
Vol/bind46
Udgave nummer4
Sider (fra-til)305-311
ISSN0014-2972
DOI
StatusUdgivet - apr. 2016

ID: 46031025